Treatment of haemophilia: From replacement to gene therapy

White, 2001, for the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definitions in hemophilia. Recommendation of the Scientific Subcommittee on factor VIII and factor IX, Thromb Haemost, 85, 560, 10.1055/s-0037-1615621 Bolton-Maggs, 2003, Haemophilias A and B, Lancet, 361, 1801, 10.1016/S0140-6736(03)13405-8 Mannucci, 2018, Miracle of haemophilia drugs: personal views about a few main players, Haemophilia, 24, 557, 10.1111/hae.13519 Mannucci, 2020, Hemophilia therapy: the future has begun, Haematologica, 105, 545, 10.3324/haematol.2019.232132 Mancuso, 2021, The changing treatment landscape in hemophilia: from standard half-life clotting factor concentrates to gene editing, Lancet, 397, 630, 10.1016/S0140-6736(20)32722-7 Oldenburg, 2004, Molecular basis of hemophilia A, Haemophilia, 10 Suppl 4, S133, 10.1111/j.1365-2516.2004.01005.x Sengupta, 2015, In silico analyses of missense mutation in coagulation factor VIII: identification of severity determinant of haemophilia A, Hamophilia, 21, 662, 10.1111/hae.12662 Lillicrap, 1998, The molecular basis of haemophilia B, Haemophilia, 4, 350, 10.1046/j.1365-2516.1998.440350.x Oldenburg, 2015, Optimal treatment strategies for hemophilia: achievement and limitations of current prophylactic regimens, Blood, 125, 2038, 10.1182/blood-2015-01-528414 Srivastava, 2020, WFH guidelines for the management of hemophilia. 3rd edition, Haemophilia, 26, 1, 10.1111/hae.14046 Iorio, 2017, Target plasma factor levels for personalized treatment in haemophila: a Delphi consensus, Haemophilia, 23, e170, 10.1111/hae.13215 Tiede, 2020, Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model, Haematologica López-Fernández, 2016, Spanish Consensus Guidelines on prophylaxis with bypassing agents in patients with haemophilia and inhibitors, Thromb Haemost, 115, 872, 10.1160/TH15-07-0568 Young, 2018, How I treat children with haemophilia and inhibitors, Br J Haematol, 186, 400, 10.1111/bjh.15942 Ljung, 2019, Inhibitors in haemophilia A and B: management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients, Eur J Haematol, 102, 111, 10.1111/ejh.13193 Collins, 2014, Recombinant long acting glycoPEGlylated factor IX in haemophilia B: a multinational randomized phase 3 trial, Blood, 124, 3880, 10.1182/blood-2014-05-573055 Mahlangu, 2014, Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A, Blood, 123, 317, 10.1182/blood-2013-10-529974 Madhi, 2015, Role of enhanced half-life factor VIII and IX in the treatment of haemophilia, Br J Haematol, 169, 768, 10.1111/bjh.13360 Oldenburg, 2017, Emicizumab prophylaxis in hemophilia A with inhibitors, N Engl J Med, 377, 809, 10.1056/NEJMoa1703068 Mahlangu, 2018, Emicizumab prophylaxis in patients who have hemophilia A without inhibitors, N Engl J Med, 379, 811, 10.1056/NEJMoa1803550 Shima, 2019, A multicentre, open-label study of emicizumab given every 2 or 4 weks in children with hemophila A without inhibitors, Haemophilia, 25, 979, 10.1111/hae.13848 Pipe, 2019, Efficacy, safety and pharmacokinetics of emicizumab prophylaxis given every 4 weks in people with hemophilia A (HAVEN 4): a multicenter, open-label non-randomised phase 3 study, Lancet Hematol, 6, e295, 10.1016/S2352-3026(19)30054-7 Young, 2019, A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors, Blood, 134, 2127, 10.1182/blood.2019001869 Callaghan, 2020, Long-term outcomes with emicizumab prophylaxis for hemophilia A with/without FVIII inhibitors from the HAVEN 1-4 studies, Blood Carcao, 2021, Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors, Expert Rev Hematol, 27, 1 Pipe, 2019, Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study, Lancet Haematol, 6, e295, 10.1016/S2352-3026(19)30054-7 Pasi, 2017, Targeting of antithrombin in hemophilia A or B with RNAi therapy, N Engl J Med, 377, 819, 10.1056/NEJMoa1616569 Weyand, 2019, New therapies for hemophilia, Blood, 133, 389, 10.1182/blood-2018-08-872291 Callagham, 2018, Novel therapeutics for hemophilia and other bleeding disorders, Blood, 132, 23, 10.1182/blood-2017-09-743385 Eichler, 2019, Conzizumab restores thrombin generation potential in patients with haemophilia: pharmacokinetic/pharmacodynamics modelling results of concizumab ohase 1/1b data, Haemophilia, 25, 60, 10.1111/hae.13627 Shapiro, 2019, Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results, Blood, 134, 1973, 10.1182/blood.2019001542 Pasi, 2020, Multiyear follow-up of AAV5-hFVIII-SQgene therapy for hemophilia A, N Engl J Med, 382, 29, 10.1056/NEJMoa1908490 Peyvandi, 2019, Clinical advances in gene therapy updates on clinical trials of gene therapy in haemophilia, Haemophilia, 25, 738, 10.1111/hae.13816 Pipe, 2020, Delivering on the promise of gene therapy for haemophilia, Haemophilia George, 2020, Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B, Mol Ther, 28, 2073, 10.1016/j.ymthe.2020.06.001 Croteau, 2021, 2021 Clinical trials update. Innovations in hemophilia therapy, Am J Hematol, 96, 128, 10.1002/ajh.26018 Herzog, 2017, Oral tolerance induction in hemophilia B dogs fed with transplastomic lettuce, Mol Ther, 25, 512, 10.1016/j.ymthe.2016.11.009 Spadarella, 2020, Paradigm shift for the treatment of hereditary hemophilia: towards precision medicine, Blood Rev, 39, 10.1016/j.blre.2019.100618